Further studies revealed that PD-L1 expression on tumor cells and infiltrating immune cells is associated with objective clinical responses in anti-PD-1 antibody-treated patients and may therefore represent a biomarker for clinical outcome. The gene discussed is PDCD1; the disease is neoplasm.